相关临床试验
235
11 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1921
进行中（未招募）
2
0.8%
已完成
127
54.0%
Enrolling By Invitation
1
0.4%
尚未招募
8
3.4%
招募中
19
8.1%
暂停
2
0.8%
终止
3
1.3%
Unknown
71
30.2%
撤回
2
0.8%
暂无批准数据
- A clinical trial presented at ERS Congress 2024 revealed that sulthiame, an epilepsy medication, effectively reduced obstructive sleep apnea symptoms by improving oxygen levels and decreasing breathing interruptions during sleep. - Researchers at ERS Congress discussed critical findings on lung function decline in IPF and PPF patients, demonstrating that even minor decreases in lung function significantly impact mortality risk and transplant likelihood. - The congress highlighted emerging trends in respiratory medicine, including AI-powered robotics potential in clinical care and key lessons from failed IPF trials emphasizing the need for improved trial design.
- Analysis of recent idiopathic pulmonary fibrosis (IPF) trial failures emphasizes the importance of learning from setbacks to refine future clinical trial designs. - Small sample sizes and short study durations in phase 2 trials can lead to overestimations of efficacy that do not translate to phase 3 studies. - Adaptive trial designs, rigorous statistical methods, and a focus on patient-relevant outcomes are crucial for improving IPF trial success. - Concurrent therapies in phase 3 trials that were not present in phase 2 can confound results.
